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Abstract
Background: Sjögren’s syndrome (SjS) monocytes have a pro-inflammatory phenotype, which may influence SjS
pathogenesis. MicroRNAs (miRNAs) are small endogenously expressed molecules that can inhibit protein expression
of their targeted genes and have important functions in regulating cell signaling responses. We profiled miRNAs in
SjS monocytes to identify a SjS-specific miRNA profile and determine the potential roles of miRNAs in SjS
pathogenesis.
Methods: Total RNA was extracted from healthy control (HC, n = 10), SjS (n = 18), systemic lupus erythematosus
(SLE, n = 10), and rheumatoid arthritis (RA, n = 10) peripheral blood CD14+ monocytes for miRNA microarray
analysis. To validate select miRNAs from the microarray analysis, the original cohort and a new cohort of monocyte
RNA samples from HC (n = 9), SjS (n = 12), SLE (n = 8), and RA (n = 9) patients were evaluated by quantitative reverse
transcription (RT)-PCR. Functional predictions of differentially expressed miRNAs were determined through miRNA
target prediction database analyses. Statistical analyses performed included one-way analysis of variance with
Bonferroni post tests, linear regression, and receiver operating characteristic curve analyses.
Results: MiRNAs were predominantly upregulated in SjS monocytes in comparison with controls. Quantitative
RT-PCR confirmations supported co-regulation of miR-34b-3p, miR-4701-5p, miR-609, miR-300, miR-3162-3p, and
miR-877-3p in SjS monocytes (13/30, 43.3 %) in comparison with SLE (1/17, 5.8 %) and RA (1/18, 5.6 %). MiRNA-target
pathway predictions identified SjS-associated miRNAs appear to preferentially target the canonical TGFβ signaling
pathway as opposed to pro-inflammatory interleukin-12 and Toll-like receptor/NFkB pathways.
Conclusions: Our results underscore a novel underlying molecular mechanism where SjS-associated miRNAs may
collectively suppress TGFβ signaling as opposed to pro-inflammatory interleukin-12 and Toll-like receptor/NFκB
pathways in SjS pathogenesis.
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Background
Sjögren’s syndrome (SjS) is a chronic autoimmune dis-
order that affects the exocrine glands and multiple organ
systems. The pathobiology of SjS involves the activation
of the innate immune system and development of auto-
immunity to exocrine tissues, resulting in severe dryness.
In general, SjS can be divided into primary or secondary
SjS (pSjS or sSjS) depending on co-morbid rheumatologic
or autoimmune diseases [1]. In addition, although SjS is
the second most common autoimmune condition to be
diagnosed next to rheumatoid arthritis (RA), SjS diagnosis
usually is difficult due to multiple symptoms resembling
other conditions and a lack of disease-specific diagnostic
markers [2, 3]. Devastating consequences of SjS have
prompted research endeavors to expedite SjS diagnosis
and guide SjS intervention strategies.
The precise mechanisms and sequence of events lead-
ing to salivary and ocular dysfunction are still unclear.
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Inflammatory responses in autoimmune conditions are as-
sumed to be limited based on the tissue microenviron-
ment, where tissue homeostatic processes and regulation
of inflammation are critical in curtailing chronic inflam-
mation. The innate immune cells involved in these pro-
cesses, such as macrophages, dendritic cells (DCs), and
epithelial cells, have been shown to shape lymphocyte pro-
liferation and functions during adaptive immune regula-
tion [4]. Monocytes and their derivatives of macrophages
and DCs have abnormalities in autoimmune diseases such
as systemic lupus erythematosus (SLE), RA, and SjS [5].
Monocytes represent a relatively homogenous population
of important precursor cells to peripheral macrophages
and DCs. Monocytes have innate immune functions in-
cluding immunomodulatory functions, cytokine produc-
tion, and phagocytosis [6]. Among SjS patient cell subsets,
monocytes secrete increased levels of pro-inflammatory
cytokines such as interleukin(IL)-6 and B cell-activating
factor (BAFF) upon stimulation [7], express type I inter-
feron (IFN)-regulated genes [5, 8–10], reduced NFκB in-
hibitor (IκBα) [11], and show decreased function in
phagocytosis of apoptotic cells [12]. Thus, monocytes re-
flect the inflammatory state in SjS patients [10] and ma-
ture monocytes are proposed to contribute to salivary
gland inflammation in SjS [13].
MicroRNAs (miRNAs) are naturally occurring post-
transcriptional regulators of their targeted genes and can
directly inhibit protein translation by a variety of mecha-
nisms including direct cleavage of messenger RNAs
(mRNAs) and translational repression due to disruption
of translation initiation or premature translation termin-
ation [14, 15]. MiRNAs can regulate a wide range of pro-
cesses including pro-apoptotic pathways, sensitization of
innate immune receptor signaling, and cytokine expres-
sion in a variety of autoimmune processes and disease
[16, 17]. One of the most intriguing aspects is how miR-
NAs function to cooperatively modulate cell processes
by limiting specific pathway components, and thus in re-
cent years extensive research has been performed to
characterize miRNAs and their regulation of immune re-
sponses and immune cell development. Ours and other
studies reported miRNAs are associated with SjS salivary
gland tissue inflammation [18–21] and are shown to be
upregulated in SjS peripheral blood mononuclear cells
[20–23] and in long-term cultured salivary gland-derived
epithelial cells [21]. Due to the complexity of cell
subsets and miRNA-mRNA interactions involved in
autoimmunity, it is still not well understood how
miRNA dysregulation contributes to autoimmune dis-
ease pathogenesis in human patients.
Considering possible roles of miRNAs as mediators of
inflammation, we hypothesized profiling of miRNAs in
SjS monocytes provides insight into functional implica-
tions of miRNAs in shaping the observed dysregularities.
No miRNA studies have been conducted on SjS mono-
cytes to date, let alone clarified implications of miRNAs
in SjS pathogenesis. Therefore, the objective of this study
was to profile miRNAs in SjS monocytes, focusing on
identifying SjS-specific miRNAs and predicting their po-
tential roles in SjS pathogenesis. Our study is the first to
characterize the differentially expressed miRNAs in SjS
in comparison to HC, SLE, and RA autoimmune condi-
tions and identify a potential SjS-specific miRNA profile
in SjS monocytes. Elucidation of the pathobiology of SjS
is critical not only to guide intervention strategies, but
also to expedite SjS diagnosis.
Methods
Patient and control participants
The University of Florida Institutional Review Board ap-
proved this study and written permission was obtained
from all who participated. Peripheral blood CD14+
monocytes were isolated using CD14+ whole blood isola-
tion microbeads (Miltenyi Biotec, Bergisch Gladbach,
Germany) for miRNA microarray and validation experi-
ments. Patients were diagnosed with SjS according to
the 2002 modified European-American diagnostic cri-
teria [1], pSjS (n = 21) and sSjS ( n = 9) patients were in-
cluded. Patients with pSjS were recruited when no other
rheumatic or underlying disease was identified and sSjS
participants were patients diagnosed with rheumatic or
additional autoimmune disease. Autoimmune control
participants diagnosed with SLE (n = 17) or RA (n = 18)
alone were diagnosed based on the American College of
Rheumatology criteria [24, 25]. Healthy donors with no his-
tory of autoimmune diseases were included as healthy con-
trols (HC, n = 17). Detailed patients’ demographic, clinical
and laboratory characteristics are summarized in Additional
file 1.
RNA extraction and sample preparation
Total RNA including small RNAs from frozen CD14+
peripheral blood monocytes were extracted with mir-
Vana miRNA Isolation kit (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer’s instructions. All
RNA sample preparations’ RNA yield and A260/280 ra-
tios were quantified using a NanoDrop1000 spectropho-
tometer (NanoDrop Technologies, Wilmington, DE,
USA) and RNA integrity was assessed by 2100 Bioanaly-
zer (Agilent Technologies, Santa Clara, CA, USA) prior
to microarray profiling and stored at -80 °C until use.
MiRNA microarray analysis
Microarray miRNA expression profiling experiments were
performed for each sample using one-color hybridizations
on μParaflo™ microfluidic biochip miRNA microarray
platform (LC Sciences, Houston, TX, USA) through LC
Sciences’ miRNA microarray service. The array contained
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2019 sequence-specific probes covering mature human
miRNAs (hsa-) listed in Sanger miRBase Release v.19.0 and
44 Epstein-Barr virus miRNA-specific probes. Hybridized
microarrays were scanned using an Axon GenePix 4000B
Microarray Scanner and images digitized using Array-Pro
Analyzer (MediaCybernetics, Rockville, MD, USA). Micro-
array data files were subjected background subtraction and
to robust LOWESS (locally weighted regression) multi-
array average background correction normalization. Data
adjustment included signal significance analysis and data
filtering that removed miRNAs with undetectable in-
tensity values in more than half of control samples
(Additional file 2). The log2-fold change values were
calculated for each miRNA between any two partici-
pant groups. The threshold value used to define up-
regulation or downregulation of miRNA was a log2
ratio > ± 0.5 in expression in comparison to HC group
and a value of P < 0.05 by one-way analysis of variance
(ANOVA) with Bonferroni post tests (log2-transformed
intensity values) among participant groups.
Verification of miRNA expression by quantitative reverse
transcription (qRT)-PCR
Based on highest ranked increase in expression for SjS
in comparison to HC, RA, or SLE controls, six selected
candidate miRNAs were verified by qRT-PCR to validate
the microarray results and in a separate validation co-
hort (Additional file 3). MiRNA quantification was car-
ried out applying two-step reaction using commercially
available TaqMan miRNA assays (Applied Biosystems,
Foster City, CA, USA) according to manufacturer’s pro-
tocols. Microarray control samples HC#3727 and #3839,
RA#3933, and SLE#3205 were excluded from validation
by RT-PCR due to insufficient sample volume. For rela-
tive quantification of miRNA expression levels, all sam-
ples were normalized against endogenous reference
RNA RNU6b using the comparative delta delta cycle
threshold (ΔΔCt) method (relative expression level (fold
change) = 2-(ΔCtsample-ΔCtcontrol)). To minimize experimen-
tal variation, matched samples of disease and controls
were analyzed on the same reaction plates.
Verification of gene expression by qRT-PCR
Based on miRNA target prediction three genes SMAD2,
SMAD3, and SMAD4 were selected for further verifica-
tion by qRT-PCR in HCs and pSjS monocytes. Gene
quantification was carried out using random primers for
reverse transcription (high-capacity cDNA reverse tran-
scription kit; Applied Biosystems) and TaqMan gene assay
PCR primers (Applied Biosystems) according to manufac-
turer’s protocols. For relative quantification of gene ex-
pression, all samples were normalized against endogenous
reference 18S ribosomal RNA using the comparative
ΔΔCt method. Values were log2-transformed to display
uniform scale for up- and downregulated genes.
Data analysis and statistical methods
Sample size determinations were performed prior to
microarray analyses using software PS:Power and Sample
Size Calculation version 3.1.2 [26]. With 80 % power to
detect a mean effect of 0.50 with two-sided adjusted type
I error probability α = 0.008333 and assuming within-
group standard deviation estimate of 0.30 [26], required
a sample size of ten subjects per group corresponding to
HC, SjS, SLE, and RA. One-way ANOVA followed by
Bonferroni post tests were performed as two-sided and
adjusted P < 0.05 was considered significant (GraphPad
Prism v.5 software, GraphPad Software, Inc, La Jolla,
CA, USA). Receiver operator characteristics (ROC)
curve and binary logistic regression analyses were used
to determine the potential miRNA expression value
cutoff to discriminate between HC and SjS patients
(Additional file 4). Clustering analysis of miRNA micro-
array signal values was performed using the
unsupervised hierarchical clustering method with the
Cluster 3.0 program [27] and a clustering plot generated
using TreeView software v. 1.6 [28]. MiRNA target
prediction was analyzed through use of a variety of
databases including validated miRNA targets (DIANA-
TarBase v.7.0 [29] and miRSystem program [30]) and
precomputed predicted miRNA targets (microRNA.org
2010 release (miRANDA) [31], TargetScan 6.2, RNA22
(miRANDA) [32]), summarized in Additional file 5.
Potential biological functions for selected miRNAs were
identified by miRSystem program [30]. Hsa-miR-588 has
identical seed sequence (position 1–8) with miR-4701-5p
and was utilized when database information was not
available. Kyoto Encyclopedia of Genes and Genomes
(KEGG) program (www.genome.jp/kegg/) was used to
map predictions of individual mRNA-miRNA interactions.
In addition, previously predicted and validated alternative
polyadenylation sites in genes were indicated using NCBI
AceView database for human genes [33] and RNAhybrid
program (bibiserv.techfak.uni-bielefeld.de/rnahybrid/) was
utilized to evaluate predicted miRNA and target gene
interactions.
Results
MiRNAs are differentially upregulated in SjS monocytes
Microarray expression analyses were performed with
HC, SjS, SLE, and RA monocyte samples to identify dif-
ferentially expressed miRNAs among groups (Table 1).
In general, SjS samples showed the highest level of
miRNA upregulation, followed by SLE samples with an
intermediate level of miRNA expression. Additionally, HC
and RA samples showed lower expression levels for these
miRNAs. Unsupervised hierarchical clustering (Fig. 1) of
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the microarray data comparing HC, SjS, SLE and RA
CD14+ monocytes showed p SjS (8/12, 66.7 %), s SjS (3/6,
50 %), and SLE (7/10, 70 %) samples formed a cluster.
Otherwise, most HC (7/10, 70 %) and RA (8/10, 80 %)
samples were grouped within a second cluster.
We next used qRT-PCR to verify our microarray find-
ings for selected miRNAs. These six miRNAs included
miR-34b-3p, miR-300, miR-609, miR-877-3p, miR-3162-
3p, and miR-4701-5p. The expression levels of these
miRNAs from the combined cohort of samples are pre-
sented in Fig. 2. Of note, miR-34b-3p displayed a signifi-
cant differential expression between SjS and HC or RA
from the combined cohort (Fig. 2a). In addition, miR-
4701-5p, and miR-3162-3p were significantly upregu-
lated in SjS patient samples with comparison to RA
(Fig. 2b,e). Although miR-609 and miR-300 tended to be
upregulated in SjS compared with other control groups
(Fig. 2c,d), there were no significant differences between
relative expressions. Furthermore, ROC curve analyses
were performed to determine cutoff values that maxi-
mized the specificity of discrimination between HC and
SjS samples (Fig. 2, Additional file 4).
SjS-associated monocyte miRNAs are co-expressed
MiRNAs are unlikely to be unique to a particular disease
process and co-regulation may indicate similar functions.
Therefore, we pursued characterization of their respect-
ive co-expression to determine whether a predictive
panel could be identified. Utilizing cutoff values reported
in Fig. 2 for our six selected miRNA markers, we evalu-
ated the number of upregulated miRNAs in our com-
bined cohort (Fig. 3a). Of note, 43.3 % of SjS patients
(13/30) had upregulated expression of at least two of the
six SjS-associated miRNAs. In contrast, 5.8 % SLE (1/17)
and 5.6 % RA (1/18) had at least two upregulated SjS-
associated miRNAs (Fig. 3a).
Since differentially expressed miRNAs tended to be
co-increased in SjS monocytes, we tested whether any
pairs of miRNAs displayed significant relationships in
their expression levels. Linear regression analyses indi-
cated miR-34b-3p and miR-4701-5p; miR-609 and miR-
300; and miR-3162-3p and miR-877-3p expression
levels were positively associated in SjS patients (Fig. 3b).
Additionally, miR-609 and miR-300 expression values
were positively associated in HC, SLE, and RA samples
and miR-34b-3p and miR-4701-5p were also associated in
RA patients (Additional file 6).
SjS-associated monocyte miRNAs preferentially target
TGFβ signaling pathways
High-throughput miRNA target validation strategies are
currently limited. Therefore, multiple miRNA target pre-
diction algorithms and validated miRNA-target inter-
action databases were incorporated to identify potential
functions of SjS-associated miRNAs in monocytes (sum-
marized in Additional file 5). MiRNA target prediction
was analyzed through databases for validated miRNA
targets (direct evidence) and precomputed predicted
miRNA targets (indirect evidence (weak) = 2 programs
and indirect evidence (strong) = 3 or more programs).
Our analyses further incorporated the KEGG program
to map potential miRNA-regulated pathways. The ca-
nonical transforming growth factor beta (TGFβ) signal-
ing pathway showed an average pathway coverage of
40.5 % ± 23.1 (SD) for the six SjS-associated miRNAs
(Fig. 4a). Key factors such as TGFBR3 and SMAD2 in-
volved in TGFβ signaling have direct evidence for target-
ing by miR-609 and miR-877-3p, respectively (Fig. 4b).
Additionally, MAPK pathways, which are also activated
through TGFβ signaling receptors [34], also tended to
show potential regulation (27.4 % ± 16.4 pathway cover-
age) by SjS-associated miRNAs (Fig. 4a). MiR-34b-3p has
Table 1 MicroRNA microarray log2 ratios for differentially
expressed miRNAs of interest
MiRNA SjS/HC SjS/RA SjS/SLE SLE/HC SLE/RA RA/HC
hsa-miR-346 1.04* 1.22 0.72 0.32 0.50 -0.19
hsa-miR-629-3p 1.01* 1.32 0.58 0.43 0.74 -0.31
hsa-miR-138-1-3p 1.01* 1.36 0.57 0.44 0.79 -0.35
hsa-miR-324-3p 0.57 0.83* 0.46 0.11 0.37 -0.26
hsa-miR-584-3p 0.82 1.23* 0.57 0.24 0.66 -0.41
hsa-miR-1234-3p 0.87* 1.38* 0.56* 0.31 0.82 -0.52
#hsa-miR-3162-3p 1.34* 1.82* 1.06* 0.28 0.76 -0.47
hsa-miR-4323 0.87* 1.09* 0.42 0.45 0.68 -0.22
hsa-miR-34c-3p 1.00* 1.23 0.37 0.63 0.85 -0.23
#hsa-miR-34b-3p 1.19* 1.43* 0.75 0.45 0.69 -0.24
hsa-miR-1228-3p 0.85* 1.26 0.42 0.43 0.84 -0.41
hsa-miR-4254 0.89* 1.03 0.73 0.16 0.30 -0.14
hsa-miR-765 0.25 0.92* 0.19 0.06 0.72 -0.66
#hsa-miR-877-3p 0.73 1.52* 0.55 0.18 0.97 -0.79
#hsa-miR-4701-5p 1.00 1.60* 0.73 0.27 0.87 -0.60
#hsa-miR-300 1.14* 1.09* 0.72 0.42 0.37 0.05
#hsa-miR-609 0.98* 0.97* 0.71 0.28 0.26 0.01
hsa-miR-485-3p 0.71 1.06* 0.45 0.27 0.61 -0.35
hsa-miR-466 0.45 0.13 -0.28 0.73* 0.41 0.32
hsa-miR-1273 g-3p -0.22 -0.11 -0.96* 0.74 0.85 -0.12
hsa-miR-5100 0.26 -0.35 -0.59 0.84* 0.24 0.60*
hsa-miR-3591-3p 0.49* 0.66 0.15 0.33 0.50 -0.17
hsa-miR-4270 0.47 1.39* -0.05 0.52 1.43 -0.92
hsa-miR-4778-5p 0.57 0.91* -0.05 0.62* 0.96* -0.34
miRNA microRNA, SjS Sjögren’s syndrome, HC healthy control, RA rheumatoid
arthritis, SLE systemic lupus erythematosus
#miRNAs selected for validation
*P < 0.05 one-way ANOVA with Bonferroni post tests
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direct evidence for targeting GRB2, P38/MAPK13, and
MEKK1/MAP3K1 and miR-877-3p has direct evidence for
targeting SOS1, NRAS, ERK1/MAPK1, RAC1, and HGK/
MAP4K4 (Fig. 4c). Visualization of the MAPK signaling
pathways indicated critical components of the classical
MAPK, JNK, and p38 MAPK signaling pathways may be
affected by SjS-associated miRNAs (Additional file 7A).
Furthermore, evaluation of JAK-STAT signaling cascades,
which are important for cytokine signaling cascades,
also showed potential regulation (20.0 % ± 12.2 pathway
coverage) by SjS-associated miRNAs (Fig. 4a). Of note,
miR-877-3p had direct evidence for targeting STAT6
(Fig. 4d), which codes for the IL-4/IL-13 pathway transcrip-
tion factor. In contrast, none of the SjS-associated miRNAs
were predicted to target IL-12 receptor (IL12RB1,
IL12RB2), TYK2, or STAT4 (Fig. 4d), which are involved
in the IL-12 signaling cascade (Additional file 7B). Fur-
thermore, the pro-inflammatory TLR/NFκB cascades av-
eraged 4.2 % ± 3.2 pathway coverage (Fig. 4a,e) and had no














































































































































































































Fig. 1 MiRNA expression signature in CD14+ monocytes. Microarray heat map showing unsupervised hierarchical clustering analysis of differentially
expressed miRNAs (one-way ANOVA with Bonferroni post tests, P < 0.05) for SjS (pSjS n = 12; sSjS n = 6), HC (n = 10), SLE (n = 10), and RA (n = 10)
samples. Green, low expression levels; red, high expression levels. HC healthy control, pSjS primary Sjögren’s syndrome, RA rheumatoid arthritis, SLE
systemic lupus erythematosus, SjS Sjögren’s syndrome, sSjS secondary Sjögren’s syndrome
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To identify impact of SjS-associated miRNAs on TGFβ
signaling molecule gene levels in CD14+ monocytes,
relative gene expression of SMAD2, SMAD3, and
SMAD4 were evaluated by qRT-PCR. SMAD2 and
SMAD3 gene expression levels were significantly in-
creased in pSjS monocytes compared with HCs, although
SMAD4 gene expression tended to be reduced (Fig. 5a).
Further sequence analyses of predicted miRNA target sites
revealed multiple alternative polyadenylation sites up-
stream of the predicted miRNA binding sites in the
SMAD2 and SMAD3 3′ untranslated region (UTR) [33].
In contrast, analyses of SMAD4 3′UTR indicated miR-300
could possibly interact at four sites (positions 745, 833,
1094, 1185 3’UTR) upstream of the first alternative polya-
denylation site (position 1499 [33]) and miR-609 to inter-
act downstream (position 2810) in the SMAD4 3’UTR
(Fig. 5b). Regression analyses indicated significant associa-
tions for both miR-300 and miR-609 with reductions in
SMAD4 gene expression in pSjS patient monocytes
(Fig. 5c).
Discussion
Research on gene expression in SjS CD14+ monocytes has
yielded valuable findings for the role of inflammatory
genes in SjS [5]. However, identifying master genes to
be targeted to reverse disease processes has been a chal-
lenge in the field of SjS. MiRNAs can modulate protein
expression levels by inhibiting gene translation into pro-
tein. MiRNA expression dysregulation has been re-
ported in a variety of autoimmune diseases, including
SjS [18–20, 22, 23]. However, the vast majority of previ-




Fig. 2 SjS-associated miRNAs are upregulated in CD14+ monocytes. Expression verification by qRT-PCR for combined microarray and validation
cohorts including HC (circle, n = 17), SjS (pSjS closed square, n = 21; sSjS open square, n = 9), SLE (triangle, n = 17), and RA (diamond, n = 18) samples.
Horizontal lines and bars represent mean ± SEM. Dotted line indicates cutoff value determined by ROC curve analyses (Additional file 4: Figure S2).
True positive rate (TPR, sensitivity) = true positive/(true positive + false negative), true negative rate (TNR, specificity) = true negative/(true negative +
false positive). *P < 0.05, ***P < 0.001, ****P < 0.0001 by one-way ANOVA with Bonferroni post tests. HC healthy control, pSjS primary Sjögren’s syndrome,
RA rheumatoid arthritis, SLE systemic lupus erythematosus, SjS Sjögren’s syndrome, sSjS secondary Sjögren’s syndrome
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cell populations or tissues, which may confound the fur-
ther evaluation of specific miRNA-mRNA target relation-
ships. Therefore, our study utilized miRNA microarray
analyses to screen for differentially expressed miRNAs in
SjS CD14+ monocytes in comparison with HC, RA, and
SLE. In addition, we selected six SjS-associated miRNAs
to be validated by RT-PCR and performed intensive path-
way analyses to identify potential target pathways of SjS-
associated miRNAs in CD14+ monocytes.
In general, primary and secondary SjS patients were
undifferentiated from each other and showed the highest
level of miRNA expression, whereas SLE patients tended
to have an intermediate level of expression in compari-
son to SjS patients. Unsupervised hierarchical clustering
of these miRNAs showed SjS and SLE patients clustered
together independent from HCs and RA patient miRNA
profiles (Fig. 1). These findings indicate miRNA alter-
ations in monocytes are more common in SjS regardless
of co-morbid autoimmune conditions and their dysregu-
lation may play a role in SjS and SLE. In addition, al-
though the healthy control group tended to be much
younger than autoimmune groups (Additional file 1),
they did not differ significantly based on miRNA associ-
ations with age (Additional file 8), which suggests age is
not likely to confound our results.
It is important to note the monocytes utilized in this
study were freshly isolated from peripheral blood. Mono-
cytes once activated will rapidly adhere and migrate into
affected tissues. Therefore, it was unsurprising a variety of
previously reported miRNAs associated with monocyte
activation and differentiation into DCs and macrophages,
including miR-155-5p, miR-146a-5p, miR-146b-5p, miR-
21-5p, miR-22-3p, miR-221-3p, miR-222-3p, and miR-
424-5p [35, 36] were not differentially expressed miRNAs
between SjS and control groups in our study. Indicating
upregulated SjS-associated miRNAs in monocytes are
most likely independent of immune activation stimuli
controlling monocyte maturation and differentiation.
Validation of six selected SjS-associated miRNAs
showed miR-34b-3p was upregulated in SjS patient
monocytes in comparison to HCs and RA patient mono-
cytes (Fig. 2a). MiRNAs significantly upregulated in SjS
patient monocytes in comparison to RA patients were
miR-3162-3p and miR-4701-5p (Fig. 2b,e). Notably, miR-
a
b
Fig. 3 SjS-associated miRNA expression levels are positively associated in CD14+ monocytes. a Number and percent distribution of upregulated
miRNAs in SjS (n = 30), SLE (n = 17), and RA (n = 18) patients. b Linear regression analyses were used to define associations between miRNA
expression levels in SjS patients (pSjS closed square, n = 21; sSjS open square, n = 9). Cutoff values determined by ROC curve analyses are indicated
by dotted box. P < 0.05 was considered statistically significant. HC healthy control, miRNA microRNA, RA rheumatoid arthritis, SLE systemic lupus
erythematosus, SjS Sjögren’s syndrome
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300 and miR-609 tended to be elevated in SjS samples,
although two RA patients from the validation cohort
expressed higher levels of miR-300 and miR-609
(Fig. 2c,d). Conceivably, this observed overlap in upregu-
lated SjS-associated miRNAs for SLE and RA patients
could be related to the observed co-aggregation and
similarities in serologic profiles of SjS patients with SLE
and RA [37, 38].
Because SjS-associated miRNAs were similarly upregu-
lated in SjS patients, we hypothesized SjS-associated
miRNAs may also be co-expressed in individuals. Inter-
estingly, 43.3 % of SjS patients, in comparison to 5.8 %
SLE and 5.6 % RA patients, had upregulated expression
of at least two of the six SjS-associated miRNAs ana-
lyzed (Fig 3a). Furthermore, regression analyses indi-
cated definite pairs of miRNAs showed positive
associations in SjS patients (Fig. 3b). Therefore, our data
suggests co-expression of SjS-associated miRNAs may
be especially useful in distinguishing cases of SjS. In
addition, since these SjS-associated miRNAs are not
genetically linked (Additional file 5), co-expression and
upregulation of these miRNAs in SjS may indicate
shared functions of regulating molecular pathways in
monocytes.
In general, co-expressed miRNAs can share functions
either by co-targeting individual genes or by targeting
different components of the same pathway. Our in-
depth analyses of target prediction algorithms and
verified miRNA-mRNA interactions were utilized to re-
construct potential pathways targeted by SjS-associated
miRNAs. Interestingly, canonical TGFβ signaling path-
way showed the greatest coverage of predicted targets,
averaging 40.5 % ± 23.1 (SD) pathway coverage for the
six SjS-associated miRNAs (Fig. 4a). Moreover, TGFβ re-
ceptors are well known to activate a variety of associated
signal transduction cascades, including the canonical
MAP kinase and p 38/JNK MAP kinase pathways [34].





























































































































































































































































































































Fig. 4 SjS-associated miRNAs are predicted to target canonical TGFβ signaling network. a Summary of average pathway-coverage scores for the
six SjS-associated miRNAs for TGFβ, MAPK, JAK-STAT, and TLR-NFκB signal transduction pathways. Bars represent mean percent coverage ± SD for
the six miRNAs. **P < 0.01 by one-way ANOVA with Bonferroni post tests. MiRNA target predictions for TGFβ (b), MAPK (c), JAK-STAT (d), and TLR-
NFκB (e) were analyzed through databases for validated miRNA targets (black, direct evidence) and precomputed predicted miRNA targets (light
gray, indirect evidence (weak) = 2 programs and dark gray, indirect evidence (strong) = 3 or more programs). f Visualization of predicted miRNA
targeting of canonical TGFβ signal transduction pathway
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coverage for the six SjS-associated miRNAs tested
(Fig. 4a). Previously, miR-34 family members [39, 40],
miR-609 [40], and miR-300 [41] were independently pre-
dicted to target the TGFβ signaling pathway. Specifically,
experimental data support miR-34b-3p directly targets
cAMP response element-binding (CREB)-1 transcription
factor [42] and bone morphogenetic protein (BMP)-2
[43]. In addition, miR-609 directly targeted the full-
length gene transcript of TGFβ1 [44] and TGFBR3 gene
transcript [29, 45]. MiR-300 overexpression inhibited the
TGFβ-mediated epithelial-to-mesenchymal transition in
tumor cells [46]. And miR-877-3p has been shown to
directly target SMAD2 gene transcript [29, 47]. Further-
more, we observed considerable overlap in evidence for
SjS-associated miRNAs to target ACVR2B, SMAD2,
SMAD3, and SMAD4 (Fig. 4b).
Based on our target prediction analyses, SMAD2,
SMAD3 and SMAD4 were selected for initial screening
for changes in gene expression in SjS monocytes com-
pared with HCs. Intriguingly, SMAD2 and SMAD3 gene
expression indicated significant increases in SjS mono-




Fig. 5 MiR-300 and miR-609 are associated with inhibition of SMAD4 gene expression. a Relative expression of SMAD2, SMAD3, and SMAD4 were
evaluated by qRT-PCR for SjS (n = 12) and HC (n = 10) CD14+ monocytes. Data represents log2-transformed gene expression. **P < 0.01, ***P < 0.001
by two-tailed t test. b Target prediction of SMAD4 3′UTR by miR-300 and miR-609 represents target-miRNA alignments with the highest predicted
minimum free energy (MFE). Position of alternative polyadenylation sites are indicated in the SMAD4 3′UTR. c Linear regression analyses of miR-300
and miR-609 with SMAD4 gene expression. HC healthy control, pSjS primary Sjögren’s syndrome, SjS Sjögren’s syndrome
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previously reported. Both SMAD2 and SMAD3 3’UTRs
contain multiple alternative polyadenylation sites up-
stream of predicted miRNA binding sites according to
AceView gene database [33], which we speculate could
result in failure in miRNA-directed inhibition of gene
transcript levels. Alternatively, miRNAs can also regulate
protein translation by mechanisms other than transcript
degradation [15]. However, at this time our study is lim-
ited to RNA-based analyses and monocytes are collected
analyses. Relationships between miRNAs and their post-
transcriptional inhibition of target genes will be ad-
dressed as soon as sufficient human monocytes are
collected for protein analyses.
Nevertheless, SMAD4 gene expression exhibited re-
pression in a subpopulation of pSjS patients (Fig. 5a).
The SMAD4 protein of the family of TGFβ signaling
molecules acts as an essential common mediator for
receptor-regulated SMADs to enter the nucleus. MiR-
300 and miR-609, which showed the strongest co-
association, are likely to target SMAD4 directly based on
target prediction analyses (Fig. 4b). Four miR-300 puta-
tive interaction sites are upstream of the first alternative
polyadenylation site and the best predicted interaction of
miR-300 with the lowest minimum free energy (MFE)
-15.1 kcal/mole begins at nucleotide position 833 of the
SMAD4 3’UTR as is shown in Fig. 4b. The best pre-
dicted interaction for miR-609, MFE -28.6 kcal/mole, is
relatively nearby downstream to miR-300 predicted tar-
get sites and begins at position 2810 of the SMAD4
3’UTR (Fig. 4b). Regression analyses showed SMAD4
gene expression is significantly associated with both
miR-300 and miR-609 (Fig. 4c), indicating possible co-
operative targeting of SMAD4. Although further studies
to identify target protein levels are required to define
specific targets and functions of SjS-associated miRNAs
in monocytes, our results indicate SjS-associated miR-
NAs could cooperate to modulate gene expression.
Our extensive data analyses pinpointing the TGFβ sig-
naling network prompted us to revisit potential roles of
TGFβ signaling in SjS pathogenesis. Until now the in-
volvement of TGFβ in SjS patients has been largely un-
appreciated due to previous inconsistencies in reported
TGFβ protein expression levels in SjS patient lip biopsy
tissues [48–52] and in circulation [53, 54]. Conditional
knockout of TGFβ receptors in mice have been utilized to
better identify roles of TGFβ signaling in autoimmunity.
Interestingly, TGFβ receptor 1 (TGFβR1) conditional
knockout in mice salivary glands developed glandular in-
flammation resembling SjS only in female mice [55]. Of
interest to our current study, bone marrow-derived DC-
specific deletion of TGFβ receptor 2 (TGFβR2) resulted in
multi-organ inflammation and activation of autoreactive T
and B cells [56]. TGFβR2-deficient DCs are more pro-in-
flammatory (increased stimulated TNF, IL-6, IL-12,
IL-1β, and IFNγ gene expression [56, 57]) and also have
impaired IL-4 polarization of M2 alternatively activated
regulatory macrophages [58]. Altogether these studies sig-
nify intact TGFβ signal transduction is critical for main-
taining a regulatory immune phenotype and reinforcing
DC/macrophage control of autoimmune progression.
Our target prediction analyses also identified SjS-
associated miRNAs were predicted to target members of
the JAK-STAT signaling family, averaging 20.0 % ± 16.4
coverage of signaling molecules (Fig. 4a). The MAPK
and JAK-STAT signaling pathways are well known to
affect a variety of pro-inflammatory and immune-
modulatory cascades beyond TGFβ family signaling. As
such, we propose that SjS-associated miRNAs also func-
tion by limiting the availability of shared signaling mole-
cules, which creates conditions for competition that
would ultimately favor pathways with greater abundance
of signaling molecules. Substrate competition is found in
many types of biological processes and can influence dy-
namics and steady state concentrations of a pathway
[59] as well as serve as a general signal integration strat-
egy for networks where enzymes interact with multiple
regulators and substrates [60].
Interestingly, pro-inflammatory IL-12 and IL-23 sig-
naling pathway molecules IL12RB1, IL12RB2, IL23R,
TYK2, and STAT4, were not predicted to be targeted by
SjS-associated miRNAs (Fig. 4d). Previously, IL-12p40
secretion in SjS patient monocyte-derived DCs was in-
creased and correlated with increased NFκB/RELB pro-
tein levels [61]. Likewise, our analyses of the NFκB
signaling pathway showed relatively low level of path-
way coverage (7.3 % ± 5.8) by SjS-associated miRNAs
(Fig. 4a,e). Intriguingly, SjS patient monocytes are previ-
ously shown to have increased gene expression of NFκB
transcription factors (NFKB1 and NFKB2) and display
increased inflammatory responses to BAFF and IFNγ
[7, 9, 61]. Notably, SjS patients’ monocytes also exhibit re-
duced levels of inhibitor IκBα, which is a central regulator
of NFkB activation [11] and TGFβ signaling is critical for
IκBα maintenance [62–64]. Therefore, pro-inflammatory
IL-12 and NFκB signaling pathways are presumed to be
well maintained, whereas SjS-associated miRNAs skew
regulatory TGFβ signaling responses in SjS monocytes.
Conclusions
Our study identified for the first time a miRNA signa-
ture for SjS in CD14+ monocytes, which appears to pref-
erentially target TGFβ signaling responses as opposed to
pro-inflammatory signaling pathways in monocytes. The
interplay of the opposing NFκB and TGFβ signaling
pathways is essential for coordinated cellular responses
and numerous studies have established a critical role for
intact TGFβ signaling mechanisms in controlling auto-
immunity. As such, our study provides critical insight
Williams et al. Arthritis Research & Therapy  (2016) 18:95 Page 10 of 13
into the observed increase in inflammatory responses in
SjS patient monocytes, which may possibly be related to
changes in the salivary gland as well. Furthermore, we
propose a paradigm shift in favor of defective regulatory
signaling as an underlying mechanism for the observed
pro-inflammatory phenotype in SjS monocytes. Clinical
associations with miRNAs will need to be evaluated
from a larger data set. Further examination of predicted
miRNA-targeted protein levels and signaling responses
in monocytes and in SjS salivary gland cell subsets is re-
quired to define the role of these upregulated miRNAs
in SjS pathogenesis.
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